Mond to Frid from 8:30 till 20:00
admin@peptworld.com
+351 964 943 024
en
Cart
0
0.00 €

PE-22-28

Out of stock

PE-22-28 is a synthetic heptapeptide (a chain of seven amino acids: GVSWGLR) currently being researched for its potent antidepressant and neuroprotective properties. It is a shortened, more stable version of spadin, a naturally occurring peptide that blocks the TREK-1 potassium channel in the brain.

Functions and Benefits:

Research suggests PE-22-28 offers several neurological advantages:

  • Rapid Antidepressant Effects: Unlike traditional SSRIs that can take weeks to work, PE-22-28 has shown antidepressant-like effects in animal models within just four days of treatment.
  • TREK-1 Channel Inhibition: It specifically blocks TREK-1 channels, which are often overactive in depressive states. This blockage increases neuronal excitability and helps regulate mood.
  • Neurogenesis and Synaptogenesis: It stimulates the growth of new neurons and the formation of new synaptic connections in the hippocampus, a brain region critical for mood and memory.
  • Cognitive and Post-Stroke Support: Studies indicate it may help reduce motor and cognitive deficits after a stroke and assist in managing post-stroke depression (PSD).
  • High Potency and Stability: It is significantly more potent than its parent compound, spadin, and remains active in the body for up to 23 hours. [1, 2, 3, 4, 5, 6, 7, 8, 9]

Safety and Regulatory Status

  • Not FDA Approved: PE-22-28 is currently classified as a research chemical and is not approved by the FDA for human use or medical treatment.
  • Side Effects: While often cited as having fewer side effects than conventional antidepressants in preclinical trials, its long-term safety in humans has not yet been established through clinical trials. 
0.00 €
0.00 € / 10 mg

PE-22-28 Peptide

PE-22-28 is a synthetic heptapeptide derived from spadin and extensively studied for its potential effects on neuroplasticity, neurogenesis, and mood regulation. As a selective inhibitor of the TREK-1 potassium channel, PE-22-28 has become an important compound in neuroscience research focused on neuronal signaling and cognitive function.

Its enhanced stability and potency compared to spadin make it a promising research tool for investigating brain adaptation mechanisms and neurological recovery pathways.

Key Research Areas

  • TREK-1 potassium channel inhibition
  • Neuroplasticity research
  • Neurogenesis studies
  • Synaptic connectivity
  • Cognitive function research
  • Neurological recovery mechanisms
  • Mood regulation pathways
  • Brain resilience and adaptation

Mechanism of Action

PE-22-28 selectively inhibits TREK-1 channels, increasing neuronal excitability and supporting signaling pathways associated with neuroplasticity. Research suggests this mechanism may contribute to enhanced neuronal growth, synaptic formation, and cognitive resilience.

Studies have demonstrated its ability to stimulate neurogenesis within the hippocampus, a brain region critically involved in memory formation, learning, and emotional regulation.

Research Applications

Researchers commonly investigate PE-22-28 in studies involving:

  • Neuroplasticity and synaptic adaptation
  • Learning and memory mechanisms
  • Cognitive performance
  • Stress response pathways
  • Neurological recovery research
  • Neuroprotection studies
  • TREK-1 receptor signaling

Product Information

Product Name: PE-22-28
Category: Research Peptide
Research Area: Neuroscience & Neuroplasticity
Purity: High-Purity Research Grade
Use: Laboratory Research Only

Disclaimer

This product is intended exclusively for scientific and laboratory research purposes. It is not intended for human consumption, medical use, diagnosis, treatment, or prevention of any disease.